Allan MacLean

Learn More
It is impossible to design systems which are appropriate for all users and all situations. We believe that a useful technique is to have end users tailor their systems to match their personal work practices. This requires not only systems which can be tailored, but a culture within which users feel in control of the system and in which tailoring is the(More)
At EuroPARC, we have been exploring ways to allow physically separated colleagues to work together effectively and naturally. In this paper, we briefly discuss several examples of our work in the context of three themes that have emerged: the need to support the full range of shared work; the desire to ensure privacy without giving up unobtrusive awareness;(More)
In order to understand some problems associated with workflow, we set out an analysis of workflow systems, identifying a number of basic issues in the underlying technology. This points to the conflation of temporal and dependency information as the source of a number of these problems. We describe Freeflow, a prototype which addresses these problems using(More)
We assert that the product of user interface design should be not only the interface itself but also a rationale for why the interface is the way it is. We describe a representation for design based around a semi-formal notation which allows us explicitly to represent alternative design options and reasons for choosing among them. We illustrate the approach(More)
To assess long-term health effects of ovarian-stimulation drugs we followed-up for over 20 years a British cohort of 7355 women with ovulatory disorders, 43% of whom were prescribed ovarian-stimulation drugs, and identified a total of 274 deaths and 367 incident cancers. Relative to the general population, the cohort experienced lower mortality from most(More)
PURPOSE In 1992, we reported the first results of a randomized study in ovarian cancer, comprising two doses of cisplatin and indicated a significant difference (P = .0008) in median survival. Four years later, we now describe the results of this trial. PATIENTS AND METHODS After a median follow-up of 4 years and 9 months, 115 of 159 cases of advanced(More)